Logo image of GNLX

GENELUX CORP (GNLX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GNLX - US36870H1032 - Common Stock

4.485 USD
-0.02 (-0.55%)
Last: 12/11/2025, 2:09:42 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GNLX. GNLX was compared to 531 industry peers in the Biotechnology industry. The financial health of GNLX is average, but there are quite some concerns on its profitability. GNLX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GNLX had negative earnings in the past year.
GNLX had a negative operating cash flow in the past year.
GNLX had negative earnings in each of the past 5 years.
In the past 5 years GNLX always reported negative operating cash flow.
GNLX Yearly Net Income VS EBIT VS OCF VS FCFGNLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

GNLX's Return On Assets of -127.56% is on the low side compared to the rest of the industry. GNLX is outperformed by 81.92% of its industry peers.
The Return On Equity of GNLX (-171.45%) is worse than 67.23% of its industry peers.
Industry RankSector Rank
ROA -127.56%
ROE -171.45%
ROIC N/A
ROA(3y)-93.9%
ROA(5y)-116.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNLX Yearly ROA, ROE, ROICGNLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GNLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNLX Yearly Profit, Operating, Gross MarginsGNLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

6

2. Health

2.1 Basic Checks

GNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
GNLX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GNLX has more shares outstanding
GNLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GNLX Yearly Shares OutstandingGNLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
GNLX Yearly Total Debt VS Total AssetsGNLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -2.91, we must say that GNLX is in the distress zone and has some risk of bankruptcy.
GNLX's Altman-Z score of -2.91 is in line compared to the rest of the industry. GNLX outperforms 44.63% of its industry peers.
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.91
ROIC/WACCN/A
WACC8.82%
GNLX Yearly LT Debt VS Equity VS FCFGNLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

GNLX has a Current Ratio of 4.20. This indicates that GNLX is financially healthy and has no problem in meeting its short term obligations.
GNLX has a Current ratio of 4.20. This is comparable to the rest of the industry: GNLX outperforms 49.34% of its industry peers.
GNLX has a Quick Ratio of 4.20. This indicates that GNLX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.20, GNLX perfoms like the industry average, outperforming 50.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 4.2
GNLX Yearly Current Assets VS Current LiabilitesGNLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

3

3. Growth

3.1 Past

GNLX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.37%.
GNLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)7.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.53%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.58% on average over the next years. This is a very strong growth
Based on estimates for the next years, GNLX will show a very strong growth in Revenue. The Revenue will grow by 730.34% on average per year.
EPS Next Y9.47%
EPS Next 2Y-2.04%
EPS Next 3Y-0.19%
EPS Next 5Y23.58%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1828.68%
Revenue Next 5Y730.34%

3.3 Evolution

GNLX Yearly Revenue VS EstimatesGNLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2027 2028 2029 2030 2031 2032 200M 400M 600M
GNLX Yearly EPS VS EstimatesGNLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GNLX. In the last year negative earnings were reported.
Also next year GNLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNLX Price Earnings VS Forward Price EarningsGNLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNLX Per share dataGNLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.04%
EPS Next 3Y-0.19%

More info and screens

0

5. Dividend

5.1 Amount

GNLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENELUX CORP

NASDAQ:GNLX (12/11/2025, 2:09:42 PM)

4.485

-0.02 (-0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-09 2026-03-09/bmo
Inst Owners30.77%
Inst Owner Change4.37%
Ins Owners12.89%
Ins Owner Change35.41%
Market Cap170.65M
Revenue(TTM)N/A
Net Income(TTM)-31.87M
Analysts81.67
Price Target19.72 (339.69%)
Short Float %8.91%
Short Ratio11.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.84%
Min EPS beat(2)2.89%
Max EPS beat(2)8.8%
EPS beat(4)3
Avg EPS beat(4)-3.22%
Min EPS beat(4)-39.67%
Max EPS beat(4)15.1%
EPS beat(8)4
Avg EPS beat(8)-9.52%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.8%
EPS NY rev (1m)2.07%
EPS NY rev (3m)2.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.18
P/tB 9.18
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-1
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS0.49
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.56%
ROE -171.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.9%
ROA(5y)-116.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 315.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 4.2
Altman-Z -2.91
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)125.54%
Cap/Depr(5y)76.05%
Cap/Sales(3y)1788.63%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.53%
EPS Next Y9.47%
EPS Next 2Y-2.04%
EPS Next 3Y-0.19%
EPS Next 5Y23.58%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1828.68%
Revenue Next 5Y730.34%
EBIT growth 1Y-15.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.51%
OCF growth 3YN/A
OCF growth 5YN/A

GENELUX CORP / GNLX FAQ

What is the fundamental rating for GNLX stock?

ChartMill assigns a fundamental rating of 2 / 10 to GNLX.


What is the valuation status for GNLX stock?

ChartMill assigns a valuation rating of 0 / 10 to GENELUX CORP (GNLX). This can be considered as Overvalued.


What is the profitability of GNLX stock?

GENELUX CORP (GNLX) has a profitability rating of 0 / 10.


Can you provide the financial health for GNLX stock?

The financial health rating of GENELUX CORP (GNLX) is 6 / 10.


Can you provide the expected EPS growth for GNLX stock?

The Earnings per Share (EPS) of GENELUX CORP (GNLX) is expected to grow by 9.47% in the next year.